XML 39 R36.htm IDEA: XBRL DOCUMENT v3.20.1
LONG-TERM DEBT LONG-TERM DEBT (Tables)
 6 Months Ended
Feb. 01, 2020
Debt Disclosure [Abstract]  
Schedule of Debt
The Company’s long-term debt consisted of the following:
(in thousands)
Average Interest Rate at
February 1, 2020
 
Calendar Maturity Year
 
February 1,
2020
 
August 3,
2019
Term Loan Facility
5.90%
 
2025
 
$
1,782,000

 
$
1,864,900

ABL Credit Facility
3.40%
 
2023
 
1,187,168

 
1,080,000

Other secured loans
5.20%
 
2023-2024
 
55,408

 
57,649

Debt issuance costs, net
 
 
 
 
(50,220
)
 
(54,891
)
Original issue discount on debt
 
 
 
 
(38,380
)
 
(41,175
)
Long-term debt, including current portion
 
 
 
 
2,935,976

 
2,906,483

Less: current portion of long-term debt
 
 
 
 
(18,845
)
 
(87,433
)
Long-term debt
 
 
 
 
$
2,917,131

 
$
2,819,050
Schedule of Line of Credit Facilities
The assets included in the Condensed Consolidated Balance Sheets securing the outstanding obligations under the ABL Credit Facility on a first-priority basis, and the unused available credit and fees under the ABL Credit Facility, were as follows:
Assets securing the ABL Credit Facility (in thousands)(1):
February 1, 2020
Certain inventory assets included in Inventories and Current assets of discontinued operations
$
2,233,585

Certain receivables included in Accounts receivables, net and Current assets of discontinued operations
$
1,056,052

(1)
The ABL Credit Facility is also secured by all of the Company’s pharmacy scripts, which are included in Long-term assets of discontinued operations in the Condensed Consolidated Balance Sheets as of February 1, 2020.

Unused available credit and fees under the ABL Credit Facility (in thousands, except percentages):
February 1, 2020
Outstanding letters of credit
$
76,757

Letter of credit fees
1.375
%
Unused available credit
$
824,149

Unused facility fees
0.25
%